Reported 1 day ago
AstraZeneca is enhancing its commitment to the US market, labeling itself an 'American company' as it increases manufacturing capabilities and plans price cuts for its drugs. CEO Pascal Soriot highlighted the company's aim for 50% of its revenue to come from the US by 2030, following significant investments and a new facility in Virginia. CFO Aradhana Sarin noted that these strategic moves are driven by demand and highlight the quicker access US patients have to new therapies compared to other countries.
Source: YAHOO